- Yan M, kConFab investigators, Fox SB. Does cyclin D1 discriminate between BRCA2 and BRCAX breast cancers? Histopathology 2009;55(5):625-6
- Expression of Delta-like Ligand 4 (Dll4) and Markers of Hypoxia in Colon Cancer. Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li J, Leek RD, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston, G, Fox SB*, Harris AL*. Br J Cancer 2009;101(10):1749-57 *joint senior authors
- Huang KT, Dobrovic A, SB Fox. No evidence of promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. BMC Research Notes 2009; 2:194
- Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GE. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Med 2009, 15, 907 – 913
- Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans T, Ismail T, Li W, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox SB, Scott R, Dobrovic A, Iacopetta B. A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting. J Mol Diagn 2009, 11:543–552
- Yan M, Rayoo M, Takano EA, KConFab investigators, Fox SB. BRCA1 tumours correlate with HIF-1α phenotype and poor prognosis through modulation of post-translational hydroxylase enzyme profile expression and cellular location. Br J Cancer 209: 101, 1168–1174
- Etemadmoghadam D deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A Raeder M, AOCS Study Group , Harnett P, Lade S, Akslen L, Tinker A, Locandro B Alsop K, Chiew Y, Traficante N, Fereday S, Johnson D, Fox SB, Sellers W, Urashima M, Salvesen H, Meyerson M. Integrated Genome-wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemo-resistance in Ovarian Carcinomas. Clin Cancer Res 2009: 15(4):1417-27 [IF 6.250]
- Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, Eden CG, Miller PD, Langley SEM, Laing RW. A Randomized Controlled Trial Investigating the Effects of Celecoxib in Patients with Localized Prostate Cancer. (2009) Anticancer Res 29: 1483-1488
- Tan EY, Tan M, Campo L, Han C, Takano E, Turley H, Pezzella F, Gatter KC, Miller EKA, O’Toole S, McNeil CM, Crea P, Segara D, Sutherland R, Harris AL, Fox SB. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumors and is associated with resistance to chemotherapy. Br J Cancer 2009, 100(2): 405-11 [IF 4.635]
- Generali D, Bates GJ, Berruti A, Berruti A, Brizzi MP, Campo L, Bonari S, Bersiga A, Allevi G, Milani M, Aguggini S, Banham A, Papotti M, Dogliotti L, Bottini A, Banham A, Harris AL, Fox SB. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients Clin Cancer Res 2009, 15(3): 1046-51 [IF 6.250]
- Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonari S, Bersiga A, Allevi G, Dilani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. EGFR/MAPK/HIF-1α signalling and activated form of ERα as markers of resistance and response to primary chemo-endocrine treatment in elderly breast cancer patients. J Clin Oncol 2009; 27: 227-234
- Dobrovic A, Kristensen LS. DNA methylation, epimutations and cancer predisposition. Int J Biochem Cell Biol. 2009 41:34-39.
- Bianco-Miotto T, Hussey DJ, Day TK, O’Keefe DS, Dobrovic A. DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLOS One 2009;4:e4788. (epub)
- Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009 119:837-51
- Zhang HH, Walker F, Kiflemariam S, Whitehead RH, Williams D, Phillips WA, Mikeska T, Dobrovic A, Burgess AW. Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. Int J Cancer. 2009 125:297-307.
- Raynor MP, Stephenson SA, Pittman KB, Walsh DC, Henderson MA, Dobrovic A. Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR. J Hematol Oncol. 2009 2:24. (epub)
- Mikeska T, Dobrovic A. Validation of a primer optimisation matrix to improve the performance of reverse transcription -quantitative real-time PCR assays. BMC Res Notes. 2009 Jun 23;2:112.
- Do H, Dobrovic A. Limited copy number -high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer. 2009 8:82. (epub)
- Candiloro IL, Dobrovic A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prevention Res. 2009 2:862-7.
- Herbert KE, Morgan S, Prince HM, Westerman DA, Wolf MM, Carney DA, Yuen K, di Lulio J, Seymour JF. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia (2009) 23 2 305 – 312
- Hang Quach, Linda Mileshkin, John F. Seymour, Alvin Milner, David Ritchie, Simon Harrison, David Westerman , H. Miles Prince. Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leukemia and Lymphoma (2009) 50 2 223 - 229
|
